Namliong SkyCosmos, Inc. - Quarter Report: 2019 September (Form 10-Q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

FORM 10-Q

[ X ] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2019

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from ________ to ___________

Commission file number: 333-130606

KREIDO BIOFUELS, INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada		20-3240178
(State or Other Jurisdiction of Incorporation or Organization)		(IRS Employer Identification No.)

New Mandarin Plaza, 14 Science Museum Road, Tsim Sha Tsui East, KLN, H.K
(Address of Principal Executive Offices)		N/A
		(Zip Code)

	+852 9862 6962
	(Issuer’s Telephone Number)
	n/a
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Securities registered under Section 12(b) of the Exchange Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No []

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer, “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer [ ]

Accelerated Filer [ ]

Non-Accelerated Filer [X]

Smaller reporting company [X]

Emerging Growth Company [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [X ] No [ ]

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date. As of November 15, 2019, the Company had outstanding 1,956,452 shares of common stock, par value $0.001 per share.

PART I

FINANCIAL INFORMATION

The Condensed Consolidated Financial Statements of the Company are prepared as of September 30, 2019.

ITEM 1.FINANCIAL STATEMENTS REQUIRED BY FORM 10-Q

CONTENTS
Condensed Consolidated Balance Sheets as of September 30, 2019 and December 31, 2018 (unaudited)	4
Condensed Consolidated Statements of Operations for the three and nine month periods ended
September 30, 2019 and 2018 (unaudited)	5
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the three and
nine month periods ended September 30, 2019 and 2018 (unaudited)	6
Condensed Consolidated Statements of Cash Flows for the nine month periods ended September 30,
2019 and 2018 (unaudited)	8
Notes to the Unaudited Condensed Consolidated Financial Statements	9

Kreido Biofuels, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)

ASSETS

				September 30,		December 31,
				2019		2018
CURRENT ASSETS
	Cash			$	-	$	-
		Total Current Assets			-		-

		TOTAL ASSETS			-		-

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES

	Accounts payable			$	17,613	$	12,225
	Related party payable				27,647		12,233
		Total Current Liabilities			45,260		24,458

			Total Liabilities		45,260		24,458

STOCKHOLDERS' DEFICIT
	Preferred stock; 10,000,000 shares authorized,
	at $0.001 par value, 0 shares issued and outstanding				-		-
	Common stock; par value $ 0,001; 300,000,000 shares authorized,
	1,956,452 shares issued and outstanding				1,956		1,956
	Additional paid-in capital				48,984,877		48,984,877
	Accumulated deficit				(49,032,093)		(49,011,291)

		Total Stockholders' Deficit			(45,260)		(24,458)

		TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT		$	-	$	-

The accompanying notes are an integral part of these unaudited financial statements.

Kreido Biofuels, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)

			For the Three Months Ended				For the Nine Months Ended
			September 30,				September 30,
			2019		2018		2019		2018

REVENUES			$	-	$	-	$	-	$	-

OPERATING EXPENSES
	Professional fees			3,125		7,732		17,734		20,082
	General and administrative			682		705		3,068		3,205
		Total Operating Expenses		3,807		8,437		20,802		23,287
LOSS FROM OPERATIONS				(3,807)		(8,437)		(20,802)		(23,287)
NET LOSS			$	(3,807)	$	(8,437)	$	(20,802)	$	(23,287)
BASIC AND DILUTED LOSS PER SHARE			$	(0.00)	$	(0.00)	$	(0.01)	$	(0.01)

BASIC AND DILUTED WEIGHTED AVERAGE
NUMBER OF COMMON SHARES
OUTSTANDING				1,956,452		1,956,452		1,956,452		1,956,452

The accompanying notes are an integral part of these unaudited financial statements

Kreido Biofuels, Inc
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)
(Unaudited)

	Nine-Month Period Ended September 30, 2018

				Additional
	Common Stock			Paid-In		Accumulated
	Shares	Amount		Capital		Deficit		Total


Balance, December 31, 2017	1,956,452	$	1,956	$	48,963,527	$	(48,972,333)	$	(6,850)

Forgiveness of related party debt					21,350				21,350

Net loss	-		-		-		(23,287)		(23,287)

Balance, September 30, 2018	1,956,452	$	1,956	$	48,984,877	$	(48,995,620)	$	(8,787)

	Nine-Month Period September 30, 2019

				Additional
	Common Stock			Paid-In		Accumulated
	Shares	Amount		Capital		Deficit		Total

Balance, December 31, 2018	1,956,452	$	1,956	$	48,984,877	$	(49,011,291)	$	(24,458)

Net loss	-		-		-		(20,802)		(20,802)

Balance, September 30, 2019	1,956,452	$	1,956	$	48,984,877	$	(49,032,093)		(45,260)

The accompanying notes are an integral part of these unaudited financial statements.

Kreido Biofuels, Inc
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Cont’d)
(Unaudited)
	Three-Month Period Ended September 30, 2018

				Additional
	Common Stock			Paid-In		Accumulated
	Shares	Amount		Capital		Deficit		Total


Balance, June 30, 2018	1,956,452	$	1,956	$	48,984,877	$	(48,987,183)	$	(350)

Net loss	-		-		-		(8,437)		(8,437)

Balance, September 30, 2018	1,956,452	$	1,956	$	48,984,877	$	(48,995,620)	$	(8,787)

	Three-Month Period Ended September 30, 2019

				Additional
	Common Stock			Paid-In		Accumulated
	Shares	Amount		Capital		Deficit		Total

Balance, June 30, 2019	1,956,452	$	1,956	$	48,984,877	$	(49,028,286)	$	(41,453)

Net loss	-		-		-		(3,807)		(3,807)

Balance, September 30, 2019	1,956,452	$	1,956	$	48,984,877	$	(49,032,093)		(45,260)

The accompanying notes are an integral part of these unaudited financial statements.

Kreido Biofuels, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)

		For the Nine Months Ended
		September 30,
		2019		2018

CASH FLOWS FROM
OPERATING ACTIVITIES
	Net loss	$	(20,802)	$	(23,287)
	Adjustments to reconcile net loss to net cash
	used in operating activities:
	Changes in operating assets and liabilities:
	Decrease in related party receivable		-		3,973
	Decrease in prepaid expenses		-		2,000
	Increase (decrease) in accounts payable		5,388		(900)
	Net Cash Used in Operating Activities		(15,414)		(18,214)

CASH FLOWS FROM INVESTING ACTIVITIES

CASH FLOWS FROM FINANCING ACTIVITIES
	Repayment of note payable		-		(11,923)
	Related party loans		15,414		30,137
	Net Cash Provided by Financing Activities		15,414		18,214

	NET INCREASE IN CASH		-		-

	CASH AT BEGINNING OF PERIOD		-		-

	CASH AT END OF PERIOD	$	-	$	-

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
	Interest	$	-	$	-
	Income Taxes	$	-	$	-

NON-CASH INVESTING AND FINANCING ACTIVITIES			-		-

	Forgiveness of related party debt	$	-	$	21,350

The accompanying notes are an integral part of these unaudited financial statements.

KREIDO BIOFUELS, INC.

Notes to Condensed Consolidated Financial Statements

September 30, 2019 and December 31, 2018

(Unaudited)

NOTE 1 - ORGANIZATION AND BUSINESS

Nature of Business

Kreido Biofuels, Inc. was incorporated as Gemwood Productions, Inc. under the laws of the State of Nevada on February 7, 2005. Gemwood Productions, Inc. changed its name to Kreido Biofuels, Inc. on November 2, 2006. The Company took its current form on January 12, 2007 when Kreido Laboratories (“Kreido Labs”) completed a reverse triangular merger with Kreido Biofuels, Inc.

Kreido Labs, formerly known as Holl Technologies Company, was incorporated on January 13, 1995, under the laws of the State of California. Since incorporation, Kreido Labs had been engaged in activities required to develop, patent and commercialize its products. Kreido Labs was the creator of reactor technology that was designed to enhance the manufacturing of a broad range of chemical products.

The cornerstone of Kreido Labs’ technology was its patented STT^® (Spinning Tube in Tube) diffusional chemical reacting system, which was both a licensable process and a licensable system. On September 20, 2008, the Company announced that due to the weakening of the economy, the continued financial market turmoil and the inability to raise needed capital to finance site construction and plant start-up costs, the Company was suspending work regarding its flagship biodiesel production plant at the Port of Wilmington, North Carolina. In November of 2017, the Company discontinued operations of its subsidiary, Kreido Labs, Inc.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the nine months ended September 30, 2019 and 2018 have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2018 audited financial statements. The results of operations for the periods ended September 30, 2019 are not necessarily indicative of the operating results for the full year.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Kreido Laboratories, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

Accounting Estimates

The preparation of the financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

KREIDO BIOFUELS, INC.

Notes to Condensed Consolidated Financial Statements

September 30, 2019 and December 31, 2018

(Unaudited)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Fair Value of Financial Instruments

Financial instruments, including cash and accrued expenses and other liabilities are carried at amounts, which reasonably approximate their fair value due to the short-term nature of these amounts or due to variable rates of interest, which are consistent with market rates.

Loss per Common Share

Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. For the nine months ended September 30, 2019 and 2018 there were no potentially dilutive debt or equity instruments issued or outstanding.

Cash and Cash Equivalents

The Company considers all highly liquid investment with an original maturity of three months or less to be cash equivalents. At September 30, 2019 and December 31, 2018, the Company did not have any cash and cash equivalents.

Stock-Based Compensation

The Company recognizes compensation expense for all stock-based compensation awards based on the grant-date fair value estimated in accordance with the provisions of ASC 718 for non-employees and ASC 505 for employees.

Income Taxes

Under ASC 740, “Income Taxes,” deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when it is more likely than not that some or all of the deferred tax assets will not be realized. As of September 30, 2019 and December 31, 2018 there were no deferred taxes due to the uncertainty of the realization of net operating loss or carry forward prior to expiration.

Fair Value of Financial Instruments

The Company follows guidance for accounting for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements on a recurring basis. Additionally, the Company adopted guidance for fair value measurement related to nonfinancial items that are recognized and disclosed at fair value in the financial statements on a nonrecurring basis. The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2 inputs are inputs other than quoted prices included within Level 1that are observable for the asset or liability, either directly or indirectly.

Level 3 inputs are unobservable inputs for the asset or liability. The carrying amounts of financial assets such as cash approximate their fair values because of the short maturity of these instruments.

KREIDO BIOFUELS, INC.

Notes to Condensed Consolidated Financial Statements

September 30, 2019 and December 31, 2018

(Unaudited)

Recent Accounting Pronouncements

The FASB established the Accounting Standards Codification (“Codification” or “ASC”) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”).

Rules and interpretative releases of the Securities and Exchange Commission (“SEC”) issued under authority of federal securities laws are also sources of GAAP for SEC registrants.

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

NOTE 3 - GOING CONCERN

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management's plan is to obtain such resources for the Company by obtaining capital from management sufficient to meet its minimal operating expenses and seeking equity and/or debt financing. However, Management cannot provide any assurances that the Company will be successful in accomplishing any of its plans, which raises substantial doubt about the ability of the Company to continue as a going concern.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

NOTE 4 – STOCKHOLDERS’ EQUITY

Common Stock

The Company’s Articles of Incorporation authorize the issuance of up to 300,000,000 common shares, par value $0.001 per share, and 10,000,000 preferred shares, also $0.001 par value. There were 1,956,452 shares of common stock outstanding at September 30, 2019 and December 31, 2018. There were no preferred shares outstanding during any periods presented.

2018

During 2018, a related party forgave an outstanding balance of $21,350 and the forgiveness of related party debt was recorded in additional paid-in capital.

2019

On July 30, 2019, the Board of Directors approved, and recommended to the stockholders for approval, a Reverse Split of the Corporation’s common stock, whereby each shareholder received one (1) new share of common stock for every one-hundred (100) shares of common stock owned on the record date. The record date is twenty days after September 9, 2019, date of filing a definitive Form 14C with the Securities Exchange Commission. Before the Reverse Split the company had 195,645,159 shares of common stock, and after the Reverse Split the company has 1,956,452 shares of common stock. The Reverse Split has been retroactively applied to all periods presented.

NOTE 5 – RELATED PARTY TRANSACTIONS

As of September 30, 2019 and December 31, 2018, the Company had a related party payable in the amount of $27,647 and $12,233, respectively. The related party payable is a shareholder in the Company, who advanced a total of $15,414 and

KREIDO BIOFUELS, INC.

Notes to Condensed Consolidated Financial Statements

September 30, 2019 and December 31, 2018

(Unaudited)

$30,137 during the nine months ended September 30, 2019 and 2018, respectively, to provide working capital for the Company. The advances are unsecured, non-interest and due on demand.

NOTE 6 – SUBSEQUENT EVENTS

The Company evaluated subsequent events from September 30, 2019 through the date the financial statements were issued. There have been no subsequent events, for which disclosure is required.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Recent Developments

None

Future Operating Plan

Results of Operations

Following is management’s discussion of the relevant items affecting results of operations for the nine month periods ended September 30, 2019 and 2018.

Revenues. The Company generated net revenues of $-0- during the three and nine months ended September 30, 2019, as compared to $-0- for the three and nine months ended September 30, 2018.

Selling, General and Administrative Expenses. Selling, general and administrative expenses for the three months ended September 30, 2019, were $682, compared to $705 during the three months ended September 30, 2018. Selling, general and administrative expenses for the nine months ended September 30, 2019, were $3,068, compared to $3,205 during the nine months ended September 30, 2018. The Company expects that salaries and consulting expenses that are cash-based, instead of share-based, will increase as we add personnel to build our business.

Professional Fees. Professional fees for the three months ended September 30, 2019, were $3,125, compared to $7,732 during the three months ended September 30, 2018. Professional fees for the nine months ended September 30, 2019, were $17,734, compared to $20,082 during the nine months ended September 30, 2018. Professional fees such as accounting and legal fees are also expected to increase.

Other Income (Expense). The Company had net other expenses of $ -0- for the three months ended September 30, 2019, compared to $ -0- during the nine months ended September 30, 2018. The Company had net other expenses of $ -0- for the nine months ended September 30, 2019, compared to $ -0- during the nine months ended September 30, 2018.

Net Loss. The Company had a net loss of $3,807 for the three months ended September 30, 2019, compared to $8,437 net loss during the three months ended September 30, 2018. The Company had a net loss of $20,802 for the nine months ended September 30, 2019, compared to $23,287 net loss during the nine months ended September 30, 2018. The decrease in net loss was due to the decrease in professional fees and general and administrative fees incurred by the Company.

Liquidity and Capital Resources

As of September 30, 2019, our primary source of liquidity consisted of $-0- in cash and cash equivalents. We hold most of our cash reserves in local checking accounts with local financial institutions. Since inception, we have financed our operations through a combination of short and long-term loans, and through the private placement of our common stock.

We have sustained significant net losses which have resulted in a total stockholders’ deficit at September 30, 2019 of $45,260, and are currently experiencing a substantial shortfall in operating capital, which raises doubt about our ability to continue as a going concern. We anticipate a net loss for the year ended December 31, 2019, and with the expected cash requirements for the coming months, without additional cash

inflows from an increase in revenues combined with continued cost-cutting or a receipt of cash from capital investment, there is substantial doubt as to the Company’s ability to continue operations.

There is presently no agreement in place with any source of financing for the Company and we cannot assure you that the Company will be able to raise any additional funds, or that such funds will be available on acceptable terms. Funds raised through future equity financing will likely be substantially dilutive to current shareholders. Lack of additional funds will materially affect the Company and its business, and may cause us to cease operations. Consequently, shareholders could incur a loss of their entire investment in the Company.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Contractual Obligations

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

Critical accounting policies

The preparation of our financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments which are based on historical experience and on various other factors that are believed to be reasonable under the circumstances. The results of their evaluation form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions and circumstances. Our significant accounting policies are more fully discussed in Note 2 to our financial statements contained herein.

Recent accounting pronouncements

The recent accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our unaudited condensed consolidated financial statements upon adoption.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to provide this information.

ITEM 4.CONTROLS AND PROCEDURES

Management’s Evaluation on Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, to allow for timely decisions regarding required disclosure.

As of September 30, 2019, the end of our third quarter, we carried out an evaluation, under the supervision of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, we concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this quarterly report. Our board of directors has only one member. We do not have a formal audit committee.

Changes in Internal Control over Financial Reporting

There have been no significant changes in our internal controls over financial reporting that occurred during the quarter ended September 30, 2019, that have materially or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II

OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we are a party to certain legal proceedings incidental to the normal course of our business including the enforcement of our rights under contracts with purchasers and suppliers. While the outcome of these legal proceedings cannot at this time be predicted with certainty, we do not expect that these proceedings will have a material effect upon our financial condition or results of operations.

ITEM 1A. RISK FACTORS

As a smaller reporting company, we are not required to provide the information required by this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIESAND USE OF PROCEEDS

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

The following documents are filed as exhibits to this Form 10-Q:

INDEX TO EXHIBITS

Number		Exhibits
3.1		Amended and Restated Certificate of Incorporation of KREIDO BIOFUELS, INC. (Previously filed)
3.2		Amended and Restated Bylaws of KREIDO BIOFUELS, INC. (Previously filed)
31.1		Certification by Chief Executive Officer, G. Reed Petersen, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification by Chief Financial Officer, G. Reed Petersen, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification by Chief Executive Officer, G. Reed Petersen, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2		Certification by Chief Financial Officer, G. Reed Petersen, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		KREIDO BIOFUELS, INC.
Date: November 15, 2019		By: /s/ Wai Lim Wong __________________
		Wai Liam Wong
		Chief Executive Officer